2. Academic Validation
  3. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain

Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain

  • Int J Antimicrob Agents. 2023 Feb 1;106738. doi: 10.1016/j.ijantimicag.2023.106738.
Juan Carlos Vázquez-Ucha 1,  Isaac Alonso-Garcia 2,  Paula Guijarro-Sánchez 2,  Cristina Lasarte-Monterrubio 2,  Laura Álvarez-Fraga 2,  Arnau Cendón-Esteve 2,  Michelle Outeda 2,  Romina Maceiras 2,  Andrea Peña-Escolano 2,  Marta Martínez-Guitián 3,  Jorge Arca-Suárez 2,  Germán Bou 2,  Alejandro Beceiro 2,  GEMARA-SEIMC/REIPI Enterobacterales Study Group
Affiliations

Affiliations

  • 1 Microbiology department of the University Hospital A Coruña (CHUAC), Institute of Biomedical Research of A Coruña (INIBIC), A Coruña. CIBER de Enfermedades Infecciosas (CIBERINFEC), Spain. Electronic address: Juan.Carlos.Vazquez.Ucha@sergas.es.
  • 2 Microbiology department of the University Hospital A Coruña (CHUAC), Institute of Biomedical Research of A Coruña (INIBIC), A Coruña. CIBER de Enfermedades Infecciosas (CIBERINFEC), Spain.
  • 3 Microbiology department of the University Hospital A Coruña (CHUAC), Institute of Biomedical Research of A Coruña (INIBIC), A Coruña. CIBER de Enfermedades Infecciosas (CIBERINFEC), Spain; NANOBIOFAR, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidad de Santiago de Compostela, 15782, Santiago de Compostela, Spain.
PMID: 36736925 DOI: 10.1016/j.ijantimicag.2023.106738
Abstract

Metallo-β-lactamase (MBL)-producing Enterobacterales are of particular concern because they are widely disseminated and difficult to treat, being resistant to almost all β-lactam Antibiotics. Aztreonam is not hydrolysed by MBLs but is labile to serine β-lactamases (SBLs), which are usually co-produced by MBL-producing Enterobacterales. Here we report the activity of aztreonam in combination with novel β-lactamase inhibitors (BLIs) against a national multicentre study collection of strains co-producing MBLs and SBLs. Fifty-five clinical isolates co-producing MBLs (41 VIM-producers, 10 NDM-producers and 4 IMP-producers) and SBLs were selected, and whole-genome Sequencing (WGS) was performed. Aztreonam, aztreonam/avibactam, aztreonam/relebactam, aztreonam/zidebactam, aztreonam/taniborbactam, aztreonam/vaborbactam and aztreonam/enmetazobactam MICs were determined. β-lactam/BLI resistance mechanisms were analysed by WGS. All BLIs decreased the aztreonam MICs for strains not susceptible to aztreonam. Aztreonam/zidebactam (MIC ≤1 mg/L for 96.4% of isolates), aztreonam/avibactam (MIC ≤1 mg/L for 92.7% of isolates) and aztreonam/taniborbactam (MIC ≤1 mg/L for 87.3 % of isolates) were the most active combinations. For other aztreonam/BLI combinations, 50-70% of the isolates yielded MICs ≤1 mg/L. WGS data revealed that mutations in PBP3, defective OmpE35/OmpK35 porins and the presence of ESBLs and class C β-lactamases were some of the resistance mechanisms involved in reduced susceptibility to aztreonam/BLIs. Combinations of aztreonam with new BLIs show promising activity against Enterobacterales co-producing MBLs and SBLs, particularly the aztreonam/zidebactam, aztreonam/avibactam and aztreonam/taniborbactam combinations. Our results show that these novel drugs may represent innovative therapeutic strategies by their use in yet unexplored combinations as solutions for difficult-to-treat infections.

Keywords

CPE, WGS; Enterobacterales; aztreonam; metallo-β-lactamase; β-lactamase inhibitors.

Figures
Products